Literature DB >> 23247597

[Non-CPAP therapies in obstructive sleep apnoea: an overview].

S Keymel1, M Kelm, W J Randerath.   

Abstract

Optimal treatment of the obstructive sleep apnoea syndrome (OSAS) requires an individually designed and interdisciplinary approach. Continuous positive airway pressure (CPAP) is accepted as the first line therapy for patients with OSAS. However, non-CPAP therapies may be indicated as supportive therapeutical approach in CPAP failure or as an alternative approach in CPAP intolerance. Overall, the level of evidence for the majority of non-CPAP therapies is low. Mandibular advancement devices as a medical non-CPAP treatment have proven to reduce respiratory disturbances to a level which may be sufficient in mild to moderate sleep apnoea. Apnoea triggered neurostimulation of upper airway muscles is an innovative approach that has shown promising results in preclinical studies. Surgical treatment has previously been performed as single level surgery of the nasal, the oropharyngeal or hypopharyngeal level. However, only tonsillectomy in the presence of tonsillar hypertrophy and maxillomandibular advancement are recommended in carefully selected cases. Due to low success rates for single level surgery, multilevel surgery has been proposed as the surgical approach for the future. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23247597     DOI: 10.1055/s-0032-1325903

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  2 in total

1.  Apps in sleep medicine.

Authors:  Andreas Stippig; Ulrich Hübers; Markus Emerich
Journal:  Sleep Breath       Date:  2014-06-03       Impact factor: 2.816

2.  Evaluation of an oral appliance in patients with mild to moderate obstructive sleep apnea syndrome intolerant to continuous positive airway pressure use: Preliminary results.

Authors:  S Cantore; A Ballini; D Farronato; G Malcangi; G Dipalma; F Assandri; U Garagiola; F Inchingolo; D De Vito; N Cirulli
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.